CVS Health Corp (CVS) Stock Price Today
Aura AI Summary
Key Stats
- $114.54BMarket Cap
- 11,064,902Volume
- HealthSector
- $110.6052W High
- $70.0852W Low
- 80 DaysTypical Hold Time
- $174.95BEnterprise Value
- 2.97%Div Yield
- 71% Sell | 29% BuyTrading Activity
Track CVS Health Corp (CVS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CVS Health Corp has traded between a low of $70.08 and a high of $110.6, highlighting its annual price range. Buy and sell CVS Health Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Most Recent News
Crescent Energy buys back assets from Devon Energy, shares drop 15%, target price $14 amid oil price and integration risks.
Crescent Energy (CRGY) plans to buy back $3.85 billion in Eagle Ford assets from Devon Energy (DVN), causing its shares to fall about 15% to $11. The deal values CRGY with upside potential if oil prices stay above $68 WTI, supported by dividend cover...

Boeing logs $10.2B in October orders but struggles with 737 MAX and 777 deliveries.
Boeing secured 165 orders worth $10.2 billion in October, showing strong demand. However, the company faces ongoing challenges ramping up deliveries, especially for its 737 MAX and 777 aircraft, which has slowed year-on-year delivery growth. Despite ...

First Phosphate reaffirmed as speculative Buy ahead of key 2027 feasibility study with strong financial backing.
First Phosphate Corp. is reaffirmed as a speculative Buy due to its strong balance sheet and significant government and export credit support, including a $212.5M SERV letter. The company’s Bégin Lamarche project is supported by these financial stren...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.